← Back to Search

Alpha-glucosidase Inhibitor

2 for Chronic Hepatitis C

Phase 2
Waitlist Available
Research Sponsored by BioWest Therapeutics Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic HCV infection.

Eligible Conditions
  • Chronic Hepatitis C

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: 2Experimental Treatment1 Intervention
Group II: 1Experimental Treatment1 Intervention
Group III: 3Active Control1 Intervention

Find a Location

Who is running the clinical trial?

BioWest Therapeutics IncLead Sponsor
6 Previous Clinical Trials
1,893 Total Patients Enrolled
Jim PankovichStudy DirectorBioWest Therapeutics Inc
6 Previous Clinical Trials
1,893 Total Patients Enrolled
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top